Platelet‐derived growth factor D: A new player in the complex cross‐talk between cholangiocarcinoma cells and cancer‐associated fibroblasts
Carmen Berasain, Matias A. Ávila – 20 May 2013
Hepatocellular cancer risk in diabetes: Not all diabetics are the same
Siddharth Singh, Preet Paul Singh – 20 May 2013
Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis
Aaron Turkish, Jean J. Luo, Jay H. Lefkowitch – 20 May 2013
Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome
Joseph E. Khabbaza, Richard A. Krasuski, Adriano R. Tonelli – 20 May 2013
Donor risk index for African American liver transplant recipients with hepatitis C virus
Nathan J. Shores, Jennifer L. Dodge, Sandy Feng, Norah A. Terrault – 20 May 2013 – African American (AA) liver transplant (LT) recipients with hepatitis C virus (HCV) have higher rates of graft loss than other racial/ethnic groups. The Donor Risk Index (DRI) predicts graft loss but is neither race‐ nor disease‐specific and may not be optimal for assessing donor risk for AA HCV‐positive LT recipients. We developed a DRI for AA with HCV with the goal of enhancing graft loss predictions. All U.S.
Reply
Elisabetta Bacchi, Carlo Negri, Giovanni Targher, Massimo Lanza, Federico Schena, Paolo Moghetti – 20 May 2013
Chronic hepatitis B infection in adolescents vaccinated at birth: An alarm bell in favor of the need for a booster?
Luisa Romanò, Rita Carsetti, Alberto E. Tozzi, Alfonso Mele, Alessandro R. Zanetti – 20 May 2013
Reply
Stefania Bruno, Ciro Tetta, Giovanni Camussi – 20 May 2013
Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis
Aaron Turkish, Jean J. Luo, Jay H. Lefkowitch – 20 May 2013
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials
Mazen Noureddin, Jessica Lam, Michael R. Peterson, Michael Middleton, Gavin Hamilton, Thuy‐Anh Le, Ricki Bettencourt, Chris Changchien, David A. Brenner, Claude Sirlin, Rohit Loomba – 20 May 2013 – The magnetic resonance imaging–estimated proton density fat fraction (MRI‐PDFF) is a novel imaging‐based biomarker that allows fat mapping of the entire liver, whereas the magnetic resonance spectroscopy–measured proton density fat fraction (MRS‐PDFF) provides a biochemical measure of liver fat in small regions of interest.